What Happened to Peptide Sciences
On March 6, 2026, one of the largest U.S.-based research-peptide vendors went dark. Here is the FDA enforcement timeline, the GLP-1 litigation that drove it, and the documented facts from industry counsel and analytics firms.
The shutdown event
At approximately 2:00 PM Eastern on Friday, March 6, 2026, the Peptide Sciences website stopped serving traffic. There was no advance notice, no published wind-down period, and no announcement on the company's social channels. Pending orders were cancelled silently. The company has not, as of this writing, published a refund or customer-service process.
According to e-commerce analytics firm Grips Intelligence, Peptide Sciences had generated an estimated $7.4 million in online sales in December 2025 alone, making the abrupt departure one of the largest single-vendor exits in the history of the U.S. research-peptide market.
FDA enforcement timeline
The shutdown followed roughly fifteen months of escalating regulatory pressure on the broader research-peptide industry. The visible inflection points:
- December 2024. The FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research over the marketing of GLP-1 receptor agonist research compounds as unapproved drugs.
- March 2024 → January 2025. Eli Lilly filed an International Trade Commission complaint against twelve vendors selling imported tirzepatide. In January 2025, the ITC issued a General Exclusion Order blocking infringing tirzepatide imports at the border.
- June 2025. FDA agents conducted a warehouse raid at Amino Asylum, forcing the vendor offline.
- September 2025. The FDA issued more than 50 additional warning letters to compounders, manufacturers, and research-supply vendors involved in GLP-1 production.
- Early 2026. The proposed SAFE Drugs Act was introduced. As drafted, it would explicitly prohibit research-chemical sales of compounds biologically identical to FDA-approved drugs without a New Drug Application — eliminating the legal gray area that high-margin GLP-1 catalogs had operated in.
- March 6, 2026. Peptide Sciences voluntarily shuts down.
Why the timing matters
Industry counsel reads the closure as a calculated exit ahead of the SAFE Drugs Act and ahead of any direct enforcement action. Analysis from Lumalex Law notes that large vendors become disproportionately visible to regulators, and that payment-processor classifications had been deteriorating across the segment throughout late 2025. The detailed timeline at PeptideLaws.com documents the FDA's shift from individual warning letters to coordinated, multi-vendor enforcement waves.
What this means for the industry
The Peptide Sciences exit consolidates the U.S. research-peptide segment around a smaller number of vendors with cleaner positioning: research-use-only labeling, no therapeutic marketing claims, public per-batch COAs, and catalogs that avoid the GLP-1 enforcement zone. Vendors still importing tirzepatide or marketing weight-loss outcomes are effectively the next regulatory targets.
For an audience of independent researchers, the practical effect is the disappearance of a familiar supplier and a reshuffled shortlist of alternatives. If you're looking for an alternative to Peptide Sciences, see our companion page on Peptide Sciences alternatives.
Frequently asked
When did Peptide Sciences shut down?
Peptide Sciences took its website offline on March 6, 2026, at approximately 2:00 PM Eastern. There was no advance announcement.
Why did Peptide Sciences shut down?
Industry coverage attributes the closure to escalating FDA enforcement against research-supply vendors, ITC import bans on tirzepatide-class compounds following Eli Lilly's complaint, and the proposed SAFE Drugs Act, which would have made the company's GLP-1 catalog explicitly illegal.
Did the FDA shut down Peptide Sciences directly?
No public FDA enforcement action specifically named Peptide Sciences. The shutdown was voluntary, but it followed more than 50 FDA warning letters issued to peer vendors and a high-profile June 2025 raid on Amino Asylum.
What about my pending order?
Peptide Sciences did not publish a refund or order-status process before going dark. Industry counsel has advised affected customers to document what they purchased and watch for fraudulent sites claiming to be Peptide Sciences under a new domain.
Where do former Peptide Sciences researchers buy now?
Former customers have moved to U.S.-based suppliers with public COAs and transparent business operations. Pure U.S. Peptides is one such option, focused on a 32-compound research catalog with public per-batch certificates.